The ASTCT webinar, 'RSV Vaccines/Monoclonals: Implications for HCT/Cellular Therapy Recipients' will air on Wednesday, October 25 at 1 PM CDT.

Respiratory syncytial virus (RSV) can lead to severe illness in immunocompromised patients, particularly in recipients of hematopoietic cell transplantation. There are no approved therapeutics although recently 2 vaccines have been approved in adults > 60 years of age and in pregnant women. During the webinar, our experts will review current data on RSV vaccines and monoclonals, discuss implications, and address potential and unmet needs in HCT/CART recipients.  

Moderator:

Roy Chemaly, MD, MPH, FACP, FIDSA; MD Anderson Cancer Center

Panelists:

• Michael Boeckh, MD, PhD; Fred Hutchinson Cancer Center
• Janet Englund, MD; Seattle Children's 
• Michael Ison, MD, MS; National Institutes of Health (NIH)

The ASTCT Committee on Practice Guidelines and the ASTCT Transplant Infectious Disease Special Interest Group also just published, Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients, if you'd like to review the guideline either before or after this webinar.